Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC72353 Bedinvetmab Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab Chemical Structure
  3. GC64017 Befotertinib

    D-0316

     Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC). Befotertinib Chemical Structure
  4. GC19063 Belizatinib

    TSR-011

     Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase. Belizatinib Chemical Structure
  5. GC65516 Bemarituzumab Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. Bemarituzumab Chemical Structure
  6. GC34216 Bevacizumab (Anti-Human VEGF, Humanized Antibody) Bevacizumab is a humanized monoclonal antibody against VEGF. Bevacizumab (Anti-Human VEGF, Humanized Antibody) Chemical Structure
  7. GC63436 Bevurogant

    BI 730357

     Bevurogant (BI 730357) is a retinoid-related orphan receptor-gamma t (RORγt) antagonist. Bevurogant Chemical Structure
  8. GC64810 Bezuclastinib

    CGT9486; PLX 9486

     Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V (0.0001 Bezuclastinib Chemical Structure
  9. GC15340 BFH772 VEGFR2 inhibitor BFH772 Chemical Structure
  10. GC33172 BGB-102 (JNJ-26483327) BGB-102 (JNJ-26483327) is a potent multi-kinase inhibitor against EGFR, HER2, and HER4 with IC50s of 9.6 nM, 18 nM and 40.3 nM, respectively. BGB-102 (JNJ-26483327) Chemical Structure
  11. GC19066 BGB-283 BGB-283 is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively. BGB-283 Chemical Structure
  12. GC10055 BGJ398

    Infigratinib, NVP-BGJ398

     An FGFR inhibitor BGJ398 Chemical Structure
  13. GC68759 BI-1622

    BI-1622 is an orally effective and highly selective HER2 (ERBB2) inhibitor with an IC50 of 7 nM. BI-1622 has a selectivity for EGFR greater than 25-fold. In transplant mouse models of H2170 and PC9 cells, BI-1622 showed high in vivo anti-tumor effects and has good activity molecular metabolism and pharmacokinetic properties.

     BI-1622 Chemical Structure
  14. GC65457 BI-3663 BI-3663 is a highly selective PTK2/FAK PROTAC (DC50=30 nM), with Cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC50 of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 linked to Pomalidomide with a linker. Anti-cancer activity. BI-3663 Chemical Structure
  15. GC38402 BI-4020 A fourth-generation and non-covalent EGFR tyrosine kinase inhibitor BI-4020 Chemical Structure
  16. GC68762 BI-4142

    BI-4142 is an effective, highly selective, orally active HER2 inhibitor with an IC50 value of 5 nM.

     BI-4142 Chemical Structure
  17. GC34488 BI-4464 BI-4464 is a highly selective ATP competitive inhibitor of PTK2/FAK, with an IC50 of 17 nM. A PTK2 ligand for PROTAC. BI-4464 Chemical Structure
  18. GC65886 BI-853520

    IN-10018

     BI 853520 (IN-10018) is an orally active and potent focal adhesion kinase (FAK) inhibitor (recombinant FAK IC50=1nM). BI 853520 shows anti-proliferative activity against cancer cells. BI-853520 Chemical Structure
  19. GC46924 BIBF 1120-13C-d3

    Nintedanib-13C-d3

     A neuropeptide with diverse biological activities BIBF 1120-13C-d3 Chemical Structure
  20. GC35516 BIBF 1202 BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM. BIBF 1202 Chemical Structure
  21. GC10815 BIBU 1361 dihydrochloride EGFR inhibitor BIBU 1361 dihydrochloride Chemical Structure
  22. GC10087 BIBX 1382

    Falnidamol;BIBX-1382;BIBX1382

     An EGFR inhibitor BIBX 1382 Chemical Structure
  23. GC50026 BIBX 1382 dihydrochloride Highly selective EGFR-kinase inhibitor BIBX 1382 dihydrochloride Chemical Structure
  24. GC19075 BLU-554

    BLU-554

     BLU-554 (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 5 nM. BLU-554 has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling. BLU-554 Chemical Structure
  25. GC19508 BLU-782

    Activin Receptor-like Kinase 2 Inhibitor 1, ALK2-IN-1, Fidrisertib

     BLU-782 is an oral precision therapy specifically designed to selectively target mutant ALK2. BLU-782 Chemical Structure
  26. GC63910 BLU-945 BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC). BLU-945 Chemical Structure
  27. GC10833 BLU9931 FGFR4 inhibitor,potent and irreversible BLU9931 Chemical Structure
  28. GC12539 BLZ945

    BLZ945

     BLZ945 (BLZ945) is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. BLZ945 Chemical Structure
  29. GC14136 BMS 599626 dihydrochloride EGFR and ErbB2 inhibitor,potent and selective BMS 599626 dihydrochloride Chemical Structure
  30. GC50330 BMS 605541 Potent VEGFR-2 inhibitor BMS 605541 Chemical Structure
  31. GC10455 BMS-509744 BMS-509744 Chemical Structure
  32. GC17773 BMS-536924

    IR/IGF-1R inhibitor

     BMS-536924 Chemical Structure
  33. GC10606 BMS-599626 Hydrochloride

    AC480;BMS-599626 HCl;BMS599626;BMS 599626;AC-480

     BMS-599626 Hydrochloride Chemical Structure
  34. GC13873 BMS-690514 BMS-690514 Chemical Structure
  35. GC16712 BMS-754807 IGF-1R/InsR inhibitor,potent and selective BMS-754807 Chemical Structure
  36. GC14214 BMS-777607

    BMS-817378

     BMS-777607 is a pan-TAM inhibitor, which shows anti-tumor activity to different types of cancer. BMS-777607 Chemical Structure
  37. GC13833 BMS-794833 Met/VEGFR-2 inhibitor,potent and ATP-competitive BMS-794833 Chemical Structure
  38. GC17772 BMS-817378 Potent ATP competitive inhibitor of Met/VEGFR2 BMS-817378 Chemical Structure
  39. GC11063 BMX-IN-1

    BMX Inhibitor 1

     A selective BMX and BTK inhibitor BMX-IN-1 Chemical Structure
  40. GC13343 Bosutinib (SKI-606)

    SKI 606

     Bosutinib (SKI-606) is an oral Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively. Bosutinib (SKI-606) Chemical Structure
  41. GC68796 Bosutinib hydrate

    SKI-606 hydrate

    Bosutinib (hydrate) is an orally available Src/Abl tyrosine kinase inhibitor with IC50 values of 1.2 nM and 1 nM, respectively.

     Bosutinib hydrate Chemical Structure
  42. GC40080 Bosutinib-d8

    SKI-606 D8

     Bosutinib-d8 is intended for use as an internal standard for the quantification of bosutinib by GC- or LC-MS. Bosutinib-d8 Chemical Structure
  43. GC38894 Bozitinib

    PLB-1001; CBT-101; Vebreltinib

     Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily. Bozitinib Chemical Structure
  44. GC65966 BPI-9016M BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma. BPI-9016M Chemical Structure
  45. GC41631 BPIQ-I

    PD 159121

     BPIQ-I is a quinazoline that inhibits the tyrosine kinase activity of the epidermal growth factor receptor (IC50 = 0.025 nM). BPIQ-I Chemical Structure
  46. GC19080 BPR1J-097 BPR1J-097 is a novel potent FLT3 inhibitor with an IC50 of 11 nM. BPR1J-097 Chemical Structure
  47. GC35544 BPR1J-097 Hydrochloride BPR1J-097 Hydrochloride is a novel and potent FLT3 inhibitor with an IC50 of 11?nM. BPR1J-097 Hydrochloride Chemical Structure
  48. GC35545 BPR1K871

    DBPR114

     BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy. BPR1K871 Chemical Structure
  49. GC18718 bpV(pic) (potassium hydrate)

    Bisperoxovanadium(pic)

     bpV(pic) is a bisperoxovanadium (bpV) compound that inhibits several different protein tyrosine phosphatases (PTPs), with selectivity for PTEN (IC50 = 31 nM). bpV(pic) (potassium hydrate) Chemical Structure
  50. GC74046 BR-cpd7 BR-cpd7 is a PROTAC degrader for fibroblast growth factor receptor FGFR1/2 with DC50 of 10 nM. BR-cpd7 Chemical Structure
  51. GC42972 Brain-Derived Acidic Fibroblast Growth Factor (1-11) (bovine) (trifluoroacetate salt)

    Brain-derived aFGF (1-11)

     Brain-derived acidic fibroblast growth factor (brain-derived aFGF) (1-11) is a peptide fragment of brain-derived aFGF. Brain-Derived Acidic Fibroblast Growth Factor (1-11) (bovine) (trifluoroacetate salt) Chemical Structure
  52. GC19084 Brigatinib

    Brigatinib

     A highly potent and selective ALK inhibitor Brigatinib Chemical Structure
  53. GC11692 Brivanib (BMS-540215)

    BMS 540215

     Brivanib (BMS-540215) (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Brivanib (BMS-540215) Chemical Structure
  54. GC14238 Brivanib Alaninate (BMS-582664)

    BMS 582664

     Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ. Brivanib Alaninate (BMS-582664) Chemical Structure
  55. GC74575 Brolucizumab

    DLX1008; ESBA 1008; RTH258

     Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab Chemical Structure
  56. GC34509 BT-13 BT-13 is a potent and selective glial cell line-derived neurotrophic factor (GDNF) receptor RET agonist independently of GFLs, promoting neurite growth from sensory neurons in vitro and attenuates experimental neuropathy in the Rat. BT-13 Chemical Structure
  57. GC72982 BT173 BT173 is a potent homeodomain interacting protein kinase 2 (HIPK2) inhibitor. BT173 Chemical Structure
  58. GC71346 BT424 BT424 is a specific HCK inhibitor. BT424 Chemical Structure
  59. GC68812 BT44

    BT44 is a selective RET activator. It can penetrate the blood-brain barrier and can be used for research on neurodegenerative diseases and diabetes.

     BT44 Chemical Structure
  60. GC10944 Butein

    2’,3,4,4’tetrahydroxy Chalcone

     Protein kinase inhibitor Butein Chemical Structure
  61. GC34529 c-Fms-IN-1 c-Fms-IN-1 is a FMS kinase inhibitor with an IC50 of 0.0008 μM. c-Fms-IN-1 Chemical Structure
  62. GC35663 c-Fms-IN-10 c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of FMS (Colony stimulating factor-1 receptor, CSF-1R) with IC50 of 2 nM. c-Fms-IN-10 Chemical Structure
  63. GC66028 c-Fms-IN-13 c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor with an IC50 value of 17 nM. c-Fms-IN-13 can be used as an anti-inflammatory agent. c-Fms-IN-13 Chemical Structure
  64. GC35664 c-Fms-IN-3 c-Fms-IN-3 is a novel c-Fms kinase inhibitor with a potential as anti-inflammatory agent and antirheumatic agent. c-Fms-IN-3 Chemical Structure
  65. GC35665 c-Fms-IN-8 c-Fms-IN-8 (compound 4a) is a colony stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor, with an IC50 of 9.1 nM. c-Fms-IN-8 Chemical Structure
  66. GC35666 c-Fms-IN-9 c-Fms-IN-9 is a c-FMS inhibitor extracted from patent WO2014145023A1, Compound Example 7. c-Fms-IN-9 inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT with IC50s of <0.01 μM and 0.1-1 μM, respectively. c-Fms-IN-9 Chemical Structure
  67. GC19106 c-Kit-IN-1 c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with IC50s of <200 nM. c-Kit-IN-1 Chemical Structure
  68. GC35705 c-Kit-IN-2 c-Kit-IN-2 is a c-KIT inhibitor with an IC50 of 82 nM, shows superior antiproliferative activities against all the three GIST cell lines, GIST882, GIST430, and GIST48, with GI50s of 3, 1, and 2 nM, respectively. c-Kit-IN-2 Chemical Structure
  69. GC38595 c-Kit-IN-3 c-Kit-IN-3 Chemical Structure
  70. GC38756 c-Kit-IN-3 D-tartrate c-Kit-IN-3 D-tartrate Chemical Structure
  71. GC38757 c-Kit-IN-3 hydrochloride c-Kit-IN-3 hydrochloride Chemical Structure
  72. GC65948 c-Kit-IN-5-1 c-Kit-IN-5 is potent inhibitor of c-Kit, with IC50s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties. c-Kit-IN-5-1 Chemical Structure
  73. GC35716 c-Met inhibitor 1 c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer. c-Met inhibitor 1 Chemical Structure
  74. GC35717 c-met-IN-1 c-met-IN-1 (compound 16) is a potent and selective c-Met inhibitor, with IC50 of 1.1 nM, with antitumor activity.. c-met-IN-1 Chemical Structure
  75. GC33203 c-Met-IN-2 c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC50 of 0.6 nM, with antitumor activity. c-Met-IN-2 Chemical Structure
  76. GC32748 CA-4948 CA-4948 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). CA-4948 Chemical Structure
  77. GC68820 Cabiralizumab

    FPA 008; Anti-Human CSF1R Recombinant Antibody

    Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab can enhance T cell infiltration and anti-tumor T cell immune response. Cabiralizumab inhibits osteoclast activation and prevents bone destruction, which can be used for research on rheumatoid arthritis (RA). Cabiralizumab can be combined with Nivolumab for lung cancer research.

     Cabiralizumab Chemical Structure
  78. GC15779 Cabozantinib (XL184, BMS-907351)

    BMS-907351, Cabozantinib

     Cabozantinib (XL184,BMS-907351) is a novel MET and VEGFR2 inhibitor that simultaneously inhibits metastasis, angiogenesis and tumor growth. Cabozantinib (XL184, BMS-907351) Chemical Structure
  79. GC12531 Cabozantinib malate (XL184) Cabozantinib malate (XL184) (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively. Cabozantinib malate (XL184) Chemical Structure
  80. GC67948 Cabozantinib-d6

    XL184-d6; BMS-907351-d6

     Cabozantinib-d6 Chemical Structure
  81. GC50024 Caffeic acid-pYEEIE Phosphopeptide ligand for src SH2 domain Caffeic acid-pYEEIE Chemical Structure
  82. GC64564 Caffeic acid-pYEEIE TFA Caffeic acid-pYEEIE TFA, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain. Caffeic acid-pYEEIE TFA Chemical Structure
  83. GC12910 Canertinib (CI-1033) Canertinib (CI-1033) (CI-1033;PD-183805) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM. Canertinib (CI-1033) Chemical Structure
  84. GC12087 Canertinib dihydrochloride

    CI-1033, PD 183805

     A pan-ErbB tyrosine kinase inhibitor Canertinib dihydrochloride Chemical Structure
  85. GC73667 Canlitinib Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2). Canlitinib Chemical Structure
  86. GC68828 Capmatinib dihydrochloride hydrate

    Capmatinib (INC280; INCB28060) dihydrochloride hydrate is an effective, orally active, selective, ATP-competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit the phosphorylation of c-MET and downstream effectors such as ERK1/2, AKT, FAK, GAB1 and STAT3/5 in the c-MET pathway. Capmatinib dihydrochloride hydrate effectively inhibits proliferation and migration of c-Met-dependent tumor cells and induces apoptosis. It exhibits anti-tumor activity in mouse models of cancer. Capmatinib dihydrochloride hydrate is mainly metabolized by CYP3A4 and aldehyde oxidase.

     Capmatinib dihydrochloride hydrate Chemical Structure
  87. GC49433 Capsiate A capsaicin analog with diverse biological activities Capsiate Chemical Structure
  88. GC72300 Caveolin-1 (82-101) amide (human, mouse, rat) Caveolin-1 (82-101) amide (human, mouse, rat) (Caveolin-1 scaffolding domain peptide) is a peptide that reverses aging-associated deleterious changes in multiple organs. Caveolin-1 (82-101) amide (human, mouse, rat) Chemical Structure
  89. GC43198 CAY10717 CAY10717 is a multi-targeted kinase inhibitor that exhibits greater than 40% inhibition of 34 of 104 kinases in an enzymatic assay at a concentration of 100 nM. CAY10717 Chemical Structure
  90. GC49094 CAY10781 An NRP-1/VEGF-A interaction inhibitor CAY10781 Chemical Structure
  91. GC74017 CC-3240 CC-3240 (compound 13) is a molecular glue degrader of CaMKK2 based on CC-8977, with the IC50 of 9 nM. CC-3240 Chemical Structure
  92. GC40054 CCT241161 CCT241161 is a multi-kinase inhibitor that inhibits B-RAF, B-RAFV600E, C-RAF, Src, and LCK (IC50s = 252, 15, 6, 15, and 3 nM, respectively). CCT241161 Chemical Structure
  93. GC19092 CCT241736 CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A Kd, 7.5 nM, IC50, 38 nM; Aurora-B Kd, 48 nM), FLT3 kinase (Kd, 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd, 38 nM) and FLT3(D835Y) (Kd, 14 nM). CCT241736 Chemical Structure
  94. GC73970 CDDD11-8 CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with Ki values of 8 and 13 nM, respectively. CDDD11-8 Chemical Structure
  95. GC32623 CE-245677 CE-245677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases with a cellular IC50s of 4.7 and 1 nM. CE-245677 Chemical Structure
  96. GC16421 Cediranib (AZD217)

    AZD 2171, ZD 2171

     Cediranib (AZD217) (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively. Cediranib (AZD217) Chemical Structure
  97. GC33004 Cediranib maleate (AZD-2171 maleate) Cediranib maleate (AZD-2171 maleate) (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively. Cediranib maleate (AZD-2171 maleate) Chemical Structure
  98. GC63458 Cedirogant

    ABBV-157

     Cedirogant (ABBV-157) is an orally active RORγt inverse agonist. Cedirogant Chemical Structure
  99. GC35651 Cenisertib

    AS-703569; R-763

     Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia. Cenisertib Chemical Structure
  100. GC73947 CEP-11981

    ESK981; BOL 303213X

     CEP-11981(ESK981; BOL 303213X) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and FGFR1, and has potential anti-tumor and anti-angiogenic effects. CEP-11981 Chemical Structure
  101. GC15145 CEP-28122 anaplastic lymphoma kinase (ALK) inhibitor CEP-28122 Chemical Structure

Items 201 to 300 of 1359 total

per page
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5

Set Descending Direction